Ibrutinib plus venetoclax rapidly eradicates CLL cells. (A) Absolute counts of circulating CLL cells in CAPTIVATE. (B) Absolute counts of normal B cells in CAPTIVATE. (C) Ratio of absolute counts of normal B cells to CLL cells in CAPTIVATE. (D) Absolute counts of circulating CLL cells in GLOW. (E) Absolute counts of normal B cells in GLOW. Data points represent median values, and error bars represent the interquartile range. For GLOW data, samples at cycle 28 were available only for patients with a best overall response of complete response (n = 6 per arm). C+O, chlorambucil plus obinutuzumab; I+V, ibrutinib plus venetoclax; Ibr, ibrutinib; IQR, interquartile range; Tx, treatment.